Clinical evaluation of metoprolol combined with sacubitril/valsartan in the treatment of post-PCI
CAI Tengfei
WANG Peizhuo
TIAN Jun
TIAN Peng
ZHENG Wuqiang
SHAN Houxue
LI Jing
Abstract：Objective To investigate the efficacy of metoprolol combined with sacubitril/valsartan in the treatment of post-percutaneous coronary intervention(PCI)and its effect on left ventricular remodeling.Methods A prospective ran-domized controlled trial was conducted.A total of 104 patients with acute myocardial infarction(AMI)undergoing PCI treated Cangzhou People's Hospital from May 2024 to May 2025 was selected and divided into a control group and an observation group using a random number table method,with 52 cases in each group.The control group was treated with metoprolol,while the observation group was treated with metoprolol combined with sacubitril/valsartan.The efficacy,cardiac function in-dicators,left ventricular remodeling indicators,laboratory indicators and major adverse cardiovascular events were compared between the two groups.Results The total effective rate in the observation group was 94.23%(49/52),significantly higher than 80.77%(42/52)in the control group(χ2=4.308,P<0.05).After treatment,the left ventricular end-diastolic dimension,left ventricular end-systolic dimension,and left ventricular mass index in the observation group were significantly lower than those in the control group,while the left ventricular ejection fraction was significantly higher((50.37±4.77)mm vs(53.95±4.28)mm,(41.22±4.16)mm vs(44.38±4.12)mm,(101.33±10.56)g/m2 vs(106.73±11.01)g/m2,(53.66±5.06)%vs(49.71±4.72)%)(t=-4.028,-3.892,-2.553,4.116,all P<0.05).After treatment,the levels of high-sensitivity C-reactive protein,interleukin-6,and N-terminal pro-B-type natriuretic peptide(NT-proBNP)in the observation group were significantly lower than those in the control group((6.01±1.02)mg/L vs(7.13±1.11)mg/L,(5.22±0.98)ng/L vs(6.73±1.02)ng/L,(262.76±38.52)pg/mL vs(308.25±41.89)pg/mL)(t=-5.358,-7.698,-5.764,all P<0.05).There was no statistically significant difference in the incidence of major adverse cardiovascular events between the observation group(3.85%(2/52))and the control group(13.46%(7/52))(χ2=1.946,P=0.163).Conclusion For post-PCI patients,metoprolol combined with sacubitril/valsartan can effectively inhibit and reduce the expression of inflammatory factors and NT-proBNP,inhibit left ventricular remodeling,and improve cardiac function,demonstrating good clinical efficacy.
Keywords：metoprololsacubitril/valsartanacute myocardial infarctionpercutaneous coronary interventionleft ven-tricular remodeling
Publication Date：2026-03-25
Online Publishing Date：2026-04-07(First online date of this platform, not the publication date of the document)
Pages：5( 373-377 )